We are 4DMT! Our mission is to boldly innovate to unlock the full potential of gene therapy for countless patients. 4DMT is a leader in next-generation AAV gene therapy discovery through its proprietary therapeutic vector evolution platform that empowers us to invent optimized and proprietary AAV vectors, each specifically tailored for the treatment of a rare disease with a high unmet medical need. We strive to become the most impactful company in the gene therapy industry. We are pioneering the development of precision gene therapies based on our proprietary AAV vectors. Our transformative discovery platform, Therapeutic Vector Evolution, enables our “disease first” approach to product discovery, design and development. We use our platform to discover custom and proprietary AAVs designed for specific tissues and diseases, which we believe will allow us to overcome known limitations of conventional AAV vectors and potentially address a broad range of both rare and large market diseases. Based on our Target Vector Profile for a disease, we select customized capsids in non-human primates from an estimated over one billion vector capsid sequences in our 37 proprietary and diverse AAV vector libraries as of August 1, 2019. We are developing a diverse pipeline in a broad range of therapeutic areas of wholly owned and partnered programs.